IL1B and metabolic dysfunction-associated steatohepatitis: The TLR9 antagonist also reversed NASH component histology, ALT elevations, and cytokine transcript levels (pro-Il1b, Il6, Tnfa) when administered after eight weeks of HFD once weekly for four weeks at the same dose while the mice remained on the HFD.